Last reviewed · How we verify
interferon γ-1b
Interferon γ-1b enhances immune responses by activating macrophages and natural killer cells, and it also has antiviral properties.
Interferon γ-1b enhances immune responses by activating macrophages and natural killer cells, and it also has antiviral properties. Used for Chronic granulomatous disease (CGD), Severe, malignant osteopetrosis.
At a glance
| Generic name | interferon γ-1b |
|---|---|
| Also known as | ACTIMMUNE® |
| Sponsor | Amgen |
| Drug class | Cytokine |
| Target | IFNGR |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This cytokine binds to the interferon gamma receptor (IFNGR), leading to the activation of the JAK-STAT signaling pathway, which results in the upregulation of genes involved in immune response and inflammation.
Approved indications
- Chronic granulomatous disease (CGD)
- Severe, malignant osteopetrosis
Common side effects
- Flu-like symptoms
- Fatigue
Key clinical trials
- Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation (PHASE2)
- Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study (PHASE3)
- Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia (PHASE3)
- Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia (PHASE3)
- Effect of IFN-γ on Innate Immune Cells (PHASE1)
- CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- interferon γ-1b CI brief — competitive landscape report
- interferon γ-1b updates RSS · CI watch RSS
- Amgen portfolio CI